Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.

miRecule, a biotechnology company developing RNA therapies, and GBI Biomanufacturing, a CDMO, entered a strategic partnership to advance the development and clinical supply of miRecule’s Antibody-RNA ...

PLANTATION, Fla. and GAITHERSBURG, Md., Jan. 28, 2025 /PRNewswire/ -- miRecule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

(MENAFN- PR Newswire) Under the agreement, GBI will leverage its expertise and state-of-the-art facilities to support miRecule in the development and clinical production of its ARC therapies.